- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 66 Years and older
- Enrollment
- 1,798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Milton, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–70
of 70
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib (Ofev®)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • New York, New York + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Matching Placebo, Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 11
- States / cities
- Danbury, Connecticut • Sarasota, Florida • Skokie, Illinois + 8 more
- Conditions
- Healthy Participants
- Interventions
- Nintedanib, BMS 986278
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Breast Cancer
- Interventions
- BIBF 1120, Phone Call
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pirfenidone, Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Ridgefield, Connecticut
- Conditions
- Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
- Interventions
- Nintedanib, Bevacizumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Ovarian Cancer
- Interventions
- Doxil (Pegylated Liposomal Doxorubicin), BIBF 1120
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Madison, Wisconsin
- Conditions
- Lung Cancer, Lung Metastases
- Interventions
- Nintedanib, Prednisone, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 12
- States / cities
- Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- Capecitabine, Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Duarte, California • Buffalo, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GLPG1690, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 66 Years and older
- Enrollment
- 1,798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Milton, Massachusetts
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • New York, New York + 3 more
- Conditions
- Neoplasms
- Interventions
- BIBW 2992, BIBF 1120
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more
- Conditions
- Healthy Participants
- Interventions
- NAL ER, Pirfenidone, Nintedanib
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Interventions
- Not listed
- Lead sponsor
- Cosmos Rx, Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- LTP001, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Kansas City, Kansas
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- BIBF 1120
- Drug
- Lead sponsor
- AA Secord
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Charlottesville, Virginia • Norfolk, Virginia
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- MNKD-201(Nintedanib DPI), Placebo
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- Fresno, California • Palm Springs, California • Doral, Florida + 5 more
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more
- Conditions
- Systemic Sclerosis
- Interventions
- BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more